Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services. by Harris, RJ et al.
Harris, RJ; Hope, VD; Morongiu, A; Hickman, M; Ncube, F; DE
Angelis, D (2011) Spatial mapping of hepatitis C prevalence in re-
cent injecting drug users in contact with services. Epidemiology and
infection. pp. 1-10. ISSN 0950-2688
Downloaded from: http://researchonline.lshtm.ac.uk/38/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Spatial mapping of hepatitis C prevalence in recent injecting
drug users in contact with services
R. J. HARRIS 1*, V. D. HOPE1,2, A. MORONGIU 1, M. HICKMAN3, F. NCUBE1
AND D. DE ANGELIS 1,4
1 Health Protection Agency, Centre for Infections, London, UK
2 Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK
3 School of Social and Community Medicine, University of Bristol, Bristol, UK
4 MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK
(Accepted 3 August 2011; ﬁrst published online 30 August 2011)
SUMMARY
In developed countries the majority of hepatitis C virus (HCV) infections occur in injecting drug
users (IDUs) with prevalence in IDUs often high, but with wide geographical diﬀerences within
countries. Estimates of local prevalence are needed for planning services for IDUs, but it is not
practical to conduct HCV seroprevalence surveys in all areas. In this study survey data from
IDUs attending specialist services were collected in 52/149 sites in England between 2006 and
2008. Spatially correlated random-eﬀects models were used to estimate HCV prevalence for all
sites, using auxiliary data to aid prediction. Estimates ranged from 14% to 82%, with larger
cities, London and the North West having the highest HCV prevalence. The methods used
generated robust estimates for each area, with a well-identiﬁed spatial pattern that improved
predictions. Such models may be of use in other areas of study where surveillance data are sparse.
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INTRODUCTION
Themain route of transmission of the hepatitis C virus
(HCV) in developed countries is through injection
drug use, which accounts for up to 80% of infections
in England and Wales [1]. Overall it is estimated that
HCV prevalence is about 50% in England, although
in other European Union countries national preva-
lence of HCV infection in injecting drug users (IDUs)
ranges from 12% to>75% [2]. There is also likely to
be great variation of HCV prevalence within individ-
ual countries as well as between them. In the UK,
serosurveillance studies suggest a substantial regional
variation [3] with a greater than threefold diﬀerence in
HCV prevalence between individual sites, e.g. from
60% in Manchester to<20% in North East England
and South Wales [4, 5]. Similar variations have been
reported within other countries, e.g. in Italy preva-
lence in IDUs ranges from 31% to 87% [2]. Clearly,
the risk of HCV infection can be very diﬀerent be-
tween areas (with estimates of HCV incidence in
IDUs in the UK ranging from <5/100 person-years
to 40/100 person-years [4, 6, 7]), and therefore op-
portunities for prevention and scale of the inter-
vention coverage required to reduce transmission also
vary [8, 9].
IDUs are a diﬃcult to reach population, partially
covered and represented by a mixture of data sources
(such as data from needle exchanges, specialist
drug treatment, prisons) [10]. Information on HCV
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prevalence in IDUs is not available through routine
laboratory surveillance of diagnostic tests, because
reporting of exposure categories is incomplete or
missing and because not all those at risk come forward
for testing. Public health surveillance of HCV infec-
tion, therefore, often relies upon sentinel and other
surveys of IDUs that purposively recruit through
community services and settings [11]. In England, the
unlinked anonymous monitoring survey (UAM) of
IDUs [12, 13] monitors the prevalence of antibodies
to HCV (anti-HCV) and HIV (anti-HIV) in those
attending a national sample of specialist services for
drug users in about one-third of 149 local Drug Action
Teams (DATs) responsible for commissioning services
in England. It is impractical and too costly to under-
take such surveys in every local area. Further, some of
the samples are too small to provide direct estimates of
local area anti-HCVprevalence in the sampled areas as
the survey’s focus is on producing national data [13].
Statistical models are therefore required to use the
available data from the survey and other auxiliary
sources to derive local estimates.
Synthetic estimation, which uses simple regression
models of prevalence in terms of chosen auxiliary
variables in the sampled areas, is commonly applied in
situations such as these to obtain estimates in areas
that have not been sampled [14–16]. However, this
approach assumes a relationship between the out-
come and the auxiliary (predictor) variables that may
be incorrect, relatively weak and subject to systematic
(e.g. spatial) variation; and does not correctly account
for uncertainty in the estimated regression coef-
ﬁcients. Random-eﬀects models [16, 17] are often used
to reduce the uncertainty of estimates by borrowing
strength via shrinkage, but do not account for the
uncertainty of estimates in the non-sampled areas,
which reduce to the simple synthetic estimator where
the random eﬀect is assumed to be zero.
Instead, we propose to overcome this problem by
assuming that neighbouring areas tend to be more
similar than distant ones, i.e. there is spatial corre-
lation. The inclusion of spatially correlated random
eﬀects then allows the estimation of random eﬀects in
non-sampled areas, also incorporating an appropriate
degree of uncertainty in the prevalence estimate
(A. Saei & R. Chambers, University of Southampton,
unpublished data). In this paper we propose models
of this form for the estimation of local HCV preva-
lence in recent IDUs in contact with services in
England, extending them to a Bayesian framework
as described by Go´mez-Rubio (N. Go´mez Rubio,
S. Best, et al., unpublished data) and, for example,
Best et al. [18].
MATERIALS AND METHODS
Data sources
The principal data source used is the UAM survey of
IDUs, which samples from harm reduction and
treatment services in selected DATs, these being
chosen to give a broad range of geographical and
urban/rural settings. Respondents voluntarily and
anonymously provide an oral ﬂuid sample for testing
[19], and complete a brief questionnaire. The survey
received multi-centre ethics committee approval. In
the analyses here only those that have injected in the
last year are considered (termed ‘recent injectors ’).
Data are in the form of a numerator and denominator
for participants from each DAT area, year, age group
and sex combination; with age split into three age
groups: 15–29, 30–44 and 45–59 years, and for the
years 2006–2008 (Table 1).
Auxiliary information on crime, uptake of beneﬁts,
population density and age structure, deprivation and
health is available from the Oﬃce of National
Statistics [20] (ONS) at the Local Authority District
(LAD) level. ONS data in terms of counts or numbers
were summed to DAT-level totals if the DAT covered
more than one LAD. Per-person rates or proportions
for each DAT were calculated using ONS estimates of
population size [21], and log rates (or logit of pro-
portions) were used as covariates in analyses to aid
the prediction of prevalence estimates.
The ﬁnal data source is the National Drug
Treatment Monitoring System [22] (NDTMS) which
collects data on drug users receiving addiction treat-
ment. This is used to relate prevalence estimates from
the UAM data to the treated population, under the
assumption that those in treatment are representative
of those in contact with all services. These data consist
of numbers of recent injectors (within the last year) in
treatment by age and sex for each DAT (Table 1).
HCV prevalence model
Observed HCV prevalence p^d, t, a, s for DAT d, year t,
age a and sex s was modelled via logistic regression,
similar to that described by Besag et al. [23], with the
following basic form:
logit(p^d, t, a, s)=aa, s+btt+bpop:1pop:1d, t . . .
+bpop:npop:nd, t+vd+ud, (1)
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where aa,s is an age-sex speciﬁc intercept, bt is the ef-
fect of year, and bpop.i (i=1, 2,7 …, n) are population-
level eﬀects from auxiliary ONS data (e.g. log rate of
drug oﬀences). The component vd is an unstructured
random eﬀect at the DAT level, distributed indepen-
dently as vd  N(0, s2v) if the area is ever sampled
in 2006–2008 and zero otherwise. The ud are con-
ditionally autoregressive terms for the spatially cor-
related random eﬀects at the DAT level. These are
conditional on the group of surrounding neighbours
(not including d), u-d, with the form
udjuxd  N
X
j2dd
uj
jddj,
s2u
jddj
 !
, (2)
where dd is the group of contiguous neighbours that
share a boundary with area d and |dd| the number of
neighbours, and the sum of the random eﬀects ud
is constrained to equal zero. Deviation from the
prevalence estimated by auxiliary information is there-
fore shared between the unstructured and spatially
correlated random eﬀects : the stronger the spatial
correlation, the more variation being explained by
the ud.
The oral ﬂuid test for antibodies to HCV (anti-
HCV) has a sensitivity of 91.7% and a speciﬁcity of
99.2% [19]. The observed prevalence p^d, t, a, s is related
to the true prevalence pd,t,a,s as described in Sweeting
et al. [3].
Overall DAT-level prevalence for DAT d in year
t, pd,t, is expressed as a weighted average of the
prevalence estimates described above, pd,t,a,s, with
weighting according to the age-sex distribution of
recent injectors in treatment from the NDTMS
data, i.e. :
pd, t=
X
a, s
pd, t, a, sNd, t, a, s
 !,X
a, s
Nd, t, a, s, (3)
where Nd,t,a,s is the number of recent injectors in DAT
d, year t, age a and sex s. This weighting relates esti-
mates from the UAM survey data to the population
of recent injectors in treatment, correcting for any
over- or under-sampling of demographic groups in
the UAM survey data.
Estimation of p^d, t, a, s in equation (1) is performed in
a Bayesian framework, requiring speciﬁcation of prior
distributions for each parameter. A uniform prior is
placed on standard deviations of unstructured and
spatial random eﬀects (sv and su), this form being
shown to have good properties for hierarchical
models [24]. Inverse gamma priors on variances were
also investigated to test robustness under diﬀerent
assumptions. All regression parameters and intercept
terms in the logistic model were given ﬂat prior dis-
tributions (priors with equal probability on the entire
real line).
Posterior distributions were obtained via Markov
Chain-Monte Carlo techniques implemented in
WinBUGS [25]. Medians and 95% credible intervals
(CrIs) were on the basis of 50 000 iterations from two
chains running in parallel, following a 5000 iteration
‘burn-in’ period. Convergence was assessed through
the use of the Brooks–Gelman diagnostic [26].
Model comparison
Various potential covariates and alternative model
formulations were investigated, with further details
Table 1. Summary of data on recent injectors from the National Drug
Treatment Monitoring System (NDTMS) in 2008 and unlinked anonymous
monitoring (UAM) survey of injecting drug users, England, 2006–2008
aggregated
Recent injectors,
NDTMS (%)
Recent injectors,
UAM (%)
UAM observed
anti-HCV
(prevalence)
Age (yr)
15–29 19 080 (35.0%) 2808 (41.6%) 836 (29.8%)
30–44 31 189 (57.2%) 3471 (51.4%) 1734 (50.0%)
45–59 4279 (7.8%) 473 (7.0%) 310 (65.5%)
Males 41 733 (76.5%) 5095 (75.5%) 2209 (43.4%)
Females 12 799 (23.5%) 1657 (24.5%) 671 (40.5%)
Total 54 341 6752 2880 (42.7%)
Anti-HCV, Antibodies to hepatitis C virus.
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shown in the Results section. Models were compared
via the deviance information criterion [27] (DIC), a
measure of model ﬁt plus a penalty for model com-
plexity, which can be expressed as DIC=D(#)+pD,
where D(#) is the posterior mean deviance and pD is
the eﬀective number of parameters in the model. We
also assessed the predictive performance of models via
leave one out cross-validation (CV) [28–30], where
data for each of the k sampled DATs are omitted in
turn and the model is estimated based on data from
the k–1 remaining DATs. Measures of discrepancy
can then be calculated using observed and predicted
values for the omitted DAT, such as the deviance,
which can then be summed across all DATs to pro-
vide a summary statistic for the model being tested.
Given that the data have a binomial distribution, the
CV deviance takes the form
devCV=
X
d=1:k
x2[rdlogpd(xd)+(ndxrd)log(1xpd(xd))],
(4)
where devCV is the sum of CV deviances, pd(xd) is
HCV prevalence estimated in DAT d with data for
DAT d omitted, and rd and nd the observed numerator
and denominator in DAT d. For clarity, the sum-
mation over year, age and sex is not shown in the
above equation. Use of equation (4) is intended to
provide an assessment of out-of-sample predictive
performance, which is a primary goal of the model
due to the large number of non-sampled DATs for
which estimates are required, and we chose models
that minimize devCV and therefore provide the closest
values to ‘unseen’ data.
RESULTS
Data from 6752 recent injectors participating in the
UAM survey during 2006–2008 were used in the
analyses. Of these, two-ﬁfths (41.6%) were aged
15–29, and a quarter (24.5%) were female (Table 1).
Female participants tended to be younger than males
with 51.2% aged 15–29 years compared to 38.4% of
males. Overall, 2880 (42.7%) tested positive for HCV
antibodies.
Of the 149 DATs, 52 were sampled during
2006–2008. The median sample size taken from each
DAT in 2008 was 32, with interquartile range 23–64,
and a range from 2 to 206. The small sample size in
some of the DATs reﬂects recruitment only through
treatment services where most of those participating
were ex-injectors (i.e. had not injected in the last year).
Of the nine government oﬃce regions, the best rep-
resented was the South East, with 10/19 (53%) DATs
sampled, while in Yorkshire and the Humber only
1/15 (7%) was sampled. Other regions ranged from
29% to 42% of DATs being sampled.
Model choice
Results comparing diﬀerent auxiliary covariates are
shown in Table 2. The model including logit pro-
portion of adults aged <35 years (proportion <35)
Table 2. Comparison statistics for models of prevalence of antibodies to hepatitis C virus in injecting drug users,
England, 2006–2008
Included covariate D(#) pD DIC
CV
deviance
Covariate
OR per S.D. sv su
None 2063.6 52.8 2116.4 964 n.a. 0.406 0.829
Proportion aged<35 yr 2062.8 51.7 2114.4 853 1.35 0.326 0.771
Drug crime 2070.9 52.1 2123.0 868 1.25 0.357 0.717
Violent crime 2067.1 53.3 2120.4 926 1.11 0.356 0.861
Sex crime 2061.0 54.1 2115.1 1048 0.94 0.452 0.838
Theft crime 2066.7 52.5 2119.2 875 1.31 0.319 0.849
Population density 2063.5 52.4 2115.9 946 1.31 0.398 0.776
Conception in under-18s 2063.7 52.8 2116.5 940 1.22 0.356 0.870
Income support claimants 2063.1 52.4 2115.4 939 1.38 0.360 0.790
Unemployment beneﬁt claimants 2064.9 52.8 2117.7 956 1.20 0.384 0.839
Environmental deprivation 2063.7 52.9 2116.6 971 1.18 0.427 0.792
D(#), Posterior mean deviance ; pD, eﬀective number of model parameters ; DIC, deviance information criteria (D(#)+pD) ;
CV, cross-validation deviance (measure of predictive performance) ; OR, odds ratio per standard deviation increase of
covariate ; sv, su, standard deviations of unstructured (v) and spatially correlated random eﬀects (u).
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gave the best DIC and CV deviance scores, although
many covariate choices had a similar DIC score. It is
interesting to note that some variables, such as sex
oﬀences, gave reasonable DIC scores but poor pre-
dictive performance. This can be explained by the in-
crease in sv, as the random eﬀects give a smooth ﬁt for
sampled DATs but do not aid in the prediction of
non-sampled DATs, for which v reduces to zero.
Choosing ‘proportion<35’ as the principal auxiliary
variable, we found that the inclusion of further co-
variates did not improve the model, with the excep-
tion of drug oﬀences. These two covariates were
therefore used in subsequent models.
Results comparing alternative model formulations,
with the omission and extension of various com-
ponents, are shown in Table 3. The use of spatially
correlated random eﬀects (u) greatly improves pre-
dictive ability and hence CV deviance increases if this
is omitted, although as mentioned above, the un-
structured eﬀects (v) take up the remaining variation
if this is omitted and this does not translate to a great
diﬀerence in DIC. The converse was true with the
omission of v : DIC is signiﬁcantly worse, but there is
actually a small improvement in CV deviance. With
the omission of both, model ﬁt is worse by both
measures ; although CV deviance is better than the v
only model, with the covariate for drug oﬀences
having a stronger eﬀect.
In terms of extending the model, DIC scores were
worse with the addition of further complexity. CV
deviance improved a little when allowing separate v
terms for each year, but this may exaggerate spatial
eﬀects and over-ﬁt to the sampled areas – the time-
varying sv are far smaller and there may be identiﬁ-
cation problems. We therefore retained the basic form
of the model ; results for model parameters are shown
in Table 4.
We compared model results using alternative priors
for variance components, testing Gamma(0.5, 0.005)
priors, as recommended by Kelsall & Wakeﬁeld [31],
Table 3. Comparison statistics for alternative models of prevalence of antibodies to hepatitis C virus in injecting
drug users, England, 2006–2008
Description D(#) pD DIC
CV
deviance
Age
<35,
OR
per S.D.
Drug
crime,
OR per
S.D. sv su
Final model 2064.9 51.7 2116.6 840 1.30 1.08 0.283 0.781
Omissions
Omission of spatial eﬀect 2065.8 53.0 2118.7 1007 1.30 1.14 0.629 n.a.
Omission of unstructured random eﬀect 2070.4 53.9 2124.3 795 1.31 1.09 n.a. 0.924
Omission of spatial and unstructured
random eﬀect
2450.9 10.0 2460.9 918 1.11 1.50 n.a. n.a.
Omission of age and sex eﬀects 2208.8 48.0 2256.8 988 1.35 1.07 0.307 0.837
Omission of year eﬀect 2062.8 50.1 2113.0 834 1.32 1.05 0.311 0.775
Extensions
Separate auxiliary covariate
eﬀects for each year
2065.3 56.0 2121.3 835 1.28 1.18 0.326 0.739
1.36 1.04
1.21 1.10
Separate u for each year 2048.7 72.4 2121.1 946 1.24 1.22 0.595 0.273
0.190
0.271
Separate v for each year 2047.7 72.9 2120.6 800 1.25 1.15 0.165 0.885
0.123
0.218
Separate u and v for each year 2046.8 103.3 2150.1 841 1.12 1.40 0.174 0.480
0.392 0.750
0.456 0.701
D(#), Posterior mean deviance ; pD, eﬀective number of model parameters ; DIC, deviance information criteria (D(#)+pD) ;
CV, cross-validation deviance (measure of predictive performance) ; OR, odds ratio per standard deviation increase of
covariate ; sv, su, standard deviations of unstructured (v) and spatially correlated random eﬀects (u).
Models use proportion of adults aged<35 years and drug crime as covariates.
Where components vary over time, values for years 2006, 2007 and 2008 are shown in order.
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and ﬂat Gamma(0.1, 0.1) priors. Results were similar
with the Gamma(0.1, 0.1) prior (sv=0.351, su=
0.697) but the large probability mass near zero for the
Gamma(0.5, 0.005) prior reduced the more weakly
identiﬁed unstructured random eﬀects, with the
spatial eﬀects becoming more pronounced to com-
pensate (sv=0.150, su=0.801). Prevalence estimates
were similar for all choices.
HCV prevalence estimates
Anti-HCV prevalence estimates ranged from 14% to
82%, with a median of 43% and interquartile range
from 32% to 54%. In contrast, observed prevalence
ranged from 5% to 77%. Model estimates are more
homogeneous due to shrinkage, and slightly higher as
they account for the imperfect sensitivity of the test. A
forest plot of anti-HCV prevalence estimates and
credible intervals for each DAT in 2008 are displayed
in Figure 1; and shaded maps of prevalence can be
seen in Appendix 1 (available online). Prevalence is
generally low in the North East and South West, with
high prevalence DATs in and around central London,
the North West, and a number of towns and cities
(Brighton, Bristol, Leeds, Nottingham, Reading,
Portsmouth).
To examine the eﬀects of model components, the
spatially correlated eﬀect u, unstructured random ef-
fect v, and eﬀects of the auxiliary variables are plotted
as shaded maps (see Appendix 1, online). The spatial
eﬀects exhibit two broad areas of increased prevalence
(beyond that predicted by auxiliary covariates) : in the
North West, and in London and the areas to its south
east ; with a broad band of lower prevalence diagon-
ally across the rest of the country. The auxiliary vari-
able for ‘proportion <35’ has a stronger eﬀect than
drug oﬀences, although patterns diﬀer in some areas,
with ‘proportion <35’ increasing odds of HCV in
most large cities, but the variable for drug oﬀences
predominantly aﬀecting London and the North West
areas. (For full listings of DAT-level model eﬀects see
Appendix 2, available online.)
DISCUSSION
Main ﬁndings
We have shown that there is substantial local vari-
ation in anti-HCV prevalence, with areas of high
prevalence concentrated in London, the North West,
parts of the South East and some major cities. We
found a relationship between the proportion of young
adults in the adult population and anti-HCV preva-
lence, although other predictors produced similar
patterns of results, which were generally insensitive to
model choice. A spatial eﬀect was well-identiﬁed in
the model, indicating that areas tend to be inﬂuenced
by their neighbours, beyond what may be predicted
from the covariates and demographic variables in-
cluded in the model.
Strengths and limitations
This work aimed to provide the best possible local-
level estimates of anti-HCV prevalence in recent
IDUs in contact with specialist services for drug users
across England. This goal was hampered by sparse
data, which we sought to overcome by using auxiliary
information that exhibits a link with anti-HCV
prevalence, and by taking advantage of spatial pat-
terns. Despite these eﬀorts, uncertainty remains in
prevalence estimates for non-sampled areas, particu-
larly in areas with unusual covariate levels and con-
trasting or imprecise spatial eﬀects. As long as this
uncertainty at the DAT level is considered we believe
Table 4. Final model for prevalence of antibodies to
hepatitis C virus in injecting drug users, England,
2006–2008, posterior medians and 95% credible
intervals
Parameter
Posterior
median 95% CrI
Odds ratios for model parameters
Age (yr)/sex group
15–29, male 0.58 0.51–0.66
15–29, female 0.51 0.42–0.60
30–44, male 1.00 (baseline)
30–44, female 1.03 0.86–1.23
45–59, male 1.59 1.25–2.02
45–59, female 1.99 1.26–3.19
Auxiliary variables
Proportion aged<35 yr 1.30 1.09–1.57
Drug crime 1.08 0.89–1.31
Year eﬀect
2006 1.00 (baseline)
2007 0.99 0.86–1.13
2008 0.95 0.82–1.10
Standard deviation of random-eﬀects components
Unstructured (sv) 0.283 0.024–0.549
Spatially structured (su) 0.781 0.442–1.126
CrI, Credible interval.
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Fig. 1. Prevalence of antibodies to hepatitis C virus in injecting drug users in contact with specialist drug services, England,
2008. Posterior medians and credible intervals for each Drug Action Team (DAT) are displayed by region. Ever-sampled
DATs (during 2006–2008) are shown with solid diamonds, non-sampled DATs with hollow diamonds.
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that these estimates are a reliable indication of the
general patterns in the anti-HCV prevalence in recent
IDUs across England.
The DAT-level prevalence estimates are weighted
according to the demographic distribution of all re-
cent injectors undergoing treatment for their drug use,
and are derived using data obtained from the sample
of specialist services collaborating in the UAM sur-
vey. However, the UAM survey recruits from both
harm reduction services (such as needle exchanges)
and drug treatment services (such as substitute pre-
scribing programmes and structured counselling)
while only clients of the latter types of service are in-
cluded in the NDTMS data. The NDTMS data de-
scribes those in treatment well ; however, it is assumed
here that it is generally representative of the charac-
teristics of recent IDUs in contact with all specialist
services. This assumption is supported by the fact
that three-quarters of the recent IDUs participating
in the UAM survey reporting needle-exchange use
also reported currently receiving substitute drug
treatment (data not shown), while others would be in
structured counselling which is not enquired of in
the survey. Of course, these DAT-level estimates
still do not necessarily reﬂect prevalence in all recent
IDUs as they do not include those not in contact
with specialist services. However, the use of specialist
services by IDUs in England is very extensive, with
considerable overlap in injectors recruited from com-
munity and treatment and any diﬀerences in HCV
prevalence largely due to diﬀerences in age or injecting
duration [5].
As far as we are aware, the assessment of spatial
models when there are non-sampled areas has not
been investigated. We argue that the use of ‘ leave one
out’ cross-validation provides the best assessment of
predictive ability in this setting. The DIC may not be
informative for assessing out-of-sample prediction, as
variation that is not explained by covariate eﬀects
may be taken up by either unstructured or spatially
structured random eﬀects, although models that make
use of spatial correlation will provide better out-of-
sample prediction. Posterior predictive model checks
have been suggested as an alternative to full cross-
validation [32], but these methods are principally
concerned with model ﬁt, and further investigation is
required to assess their application when the goal is
out-of-sample prediction.
Out estimates are based partly on auxiliary data,
chosen primarily on the basis of model selection.
However, these predictors also have plausible
interpretations: the proportion of the adult popu-
lation aged<35 years may be viewed as a measure of
urbanicity; and drug crime may act as a proxy for
severity of problem drug use. Taken together these
factors are surmised to give an indication of which
environments are more likely to experience high
levels of HCV infection. Prevalence estimates for non-
sampled areas may be sensitive to model choice, and
we therefore assessed the robustness of prevalence
estimates to the use of diﬀerent auxiliary variables.
Estimates were similar for most alternatives, although
including only drug oﬀences as a covariate decreased
the prevalence estimates for 10 DATs by 5–8% and
increased those for City of London and Isle of Wight
by 18% and 17%, respectively. This is due to high
rates of drug oﬀences relative to the proportion of
adults aged<35 years in these areas.
Findings in relation to the evidence base
The substantial geographical variation in anti-HCV
prevalence observed here is consistent with previous
studies, but allows a more formal assessment of this
phenomenon via a modelling process that provides
for the ﬁrst time prevalence estimates for all local
areas. For some DATs HCV prevalence has been es-
timated using respondent driven sampling (RDS) [33],
which is postulated to be the most reliable way to
obtain representative estimates for hidden popu-
lations [34] ; however, only IDUs that have injected in
the last 4 weeks were included. Results are available
for Bristol [35], Birmingham and Leeds (M. Hickman,
V. Hope, personal communication), showing a preva-
lence of 57% (95% CI 52–62), 38% (95% CI 33–44)
and 58% (95% CI 53–64), respectively, compared to
60% (95% CrI 50–70), 44% (95% CrI 25–61) and
51% (95% CrI 26–76) in this study. Our results are
uncertain for the non-sampled areas (Birmingham,
Leeds), and the RDS method does necessarily gener-
ate unbiased estimates [36] so no ﬁrm conclusions
may be drawn, although the results appear to follow
a broadly similar pattern for the areas covered.
Previously, estimates have only been available at a
regional level for England, and have not used the
NDTMS data to relate ﬁndings to a wider population.
These data thus complement regional and national
data, as well as strengthening local evidence.
Implications
The estimates of anti-HCV prevalence for non-
sampled areas have substantial uncertainty and need
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to be viewed with some caution; however, they will
provide DATs with a more robust indication of the
HCV prevalence in recent IDUs in contact with
specialist services than relying on regional estimates
of prevalence. This is especially so for those regions,
like the East Midlands, with very marked variations
in prevalence at the DAT level. These estimates
therefore have public health utility as they permit
more informed local commissioning of services to
prevent, diagnose and treat HCV infection in this
population group. As these estimates use routinely
available data they can be repeated over time; doing
this would allow the monitoring of local trends in
anti-HCV prevalence in IDUs, and so permit service
commissioning to adapt to these.
CONCLUSIONS
The novel approach adopted here has produced local
estimates of anti-HCV prevalence of use in informing
local public health responses. The limitations to these
estimates need to be noted and the methods employed
need further validation and reﬁnement. However,
there is potential to apply these methods to other
issues aﬀecting IDUs, such as hepatitis B infection or
even behavioural data, e.g. needle and syringe sharing
or the uptake of diagnostic testing. This approach
may also be of use in other situations where data are
sparse and local-level estimates are needed to inform
response; e.g. sexual health indicators in men who
have sex with men and sex workers or general health
issues in marginalized groups such as the homeless.
NOTE
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
hyg).
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